GRM8 and Anxiety: These effects were reversed with the type III-mGluR-specific antagonist (S)-2-amino-2-methyl-4- phosphonobutyric (Bahi, 2017), indicating that modulating mGluR8 activity with pharmacotherapy might be relevant in alcohol dependent disorders and anxiety.